|
|
ChemGenex Pharmaceuticals Limited - Comparative Business Analysis Snapshot
Business Description
ChemGenex Pharmaceuticals Limited. The Group's principal activity is operating as an integrated biopharmaceutical development company, focused on discovering and developing oncology drugs. Its product candidates include omacetaxine mepesuccinate (formerly known as Ceflatonin, homoharringtonine or HHT), which is and Quinamed (amonafide dihydrochloride). Operations are carried out in Australia and the United States of America.
Competitor Analysis
This analysis compares ChemGenex Pharmaceuticals Limited with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
